SA’s medical scheme industry regulator has rejected a call from an advocacy group for patients with autoimmune diseases to issue guidance on funding expensive specialised treatments, saying each case had to be assessed on its own merits.

The Autoimmune Alliance of SA (AASA) has been lobbying the Council for Medical Schemes (CMS) to clarify the extent to which funders must cover biologics, saying patients should not have to repeat battles previously won by other people in a similar position...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.